Skip to main content

Active Projects

#R01AA030486 Title: Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination
Start: 2022-09-10 / End: 2027-07-31 Primary Investigators: Yan, Bingfang Investigators: Blackard, Jason PhD; Brown, Jennifer PhD; Robertson, Jaime MD; Welge, Jeffrey PhD Grant Sponsor: National Institute on Alcohol Abuse and Alcoholism 1418844.00 (level: Federal)

#315660 / H79TI084035 Title: FY 2021 Screening, Brief Intervention and Referral to Treatment (SBIRT)
Start: 2021-09-30 / End: 2026-09-29 Primary Investigators: Acquavita, Shauna Grant Sponsor: Substance Abuse & Mental Health Services Administration 72832.20 (level: Federal)

#H79TI085997 Title: Alternatives to opioids for pain in the emergency department: Implementing Integrative Health approaches and expanding local nerve block initiatives
Start: 2023-09-30 / End: 2026-09-29 Primary Investigators: Freiermuth, Caroline MD Investigators: Ryan, Richard MD Grant Sponsor: Substance Abuse & Mental Health Services Administration 478958.00 (level: Federal)

#312397 / R01DA051895 Title: Role of Siglec-1 in HIV Interactions with Microglia and Astrocytes
Start: 2020-07-15 / End: 2025-04-30 Primary Investigators: Blackard, Jason PhD Grant Sponsor: National Institute on Drug Abuse 54990.20 (level: Federal)

#UG1DA013732 Title: Ohio Valley Node-Network (OVNN) of the NIDA Clinical Trials Network
Start: 2015-09-01 / End: 2025-02-28 Primary Investigators: Winhusen, T PhD Investigators: Elder, Nancy MD; Lyons, Michael MD Grant Sponsor: National Institute on Drug Abuse 16108823.00 (level: Federal)

#20-A0-S2-003671 / UG1DA013035 Title: CTN0100 - Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Phramacotherapy (RDD)
Start: 2020-09-01 / End: 2025-02-28 Primary Investigators: Winhusen, T PhD Grant Sponsor: National Institute on Drug Abuse 156125.00 (level: Federal)

#400271/R01DA056903 Title: Modeling HIV and methamphetamine-induced neuroinflammation in cerebral organoids
Start: 2022-09-01 / End: 2024-08-31 Primary Investigators: Blackard, Jason PhD Grant Sponsor: National Institute on Drug Abuse 41398.42 (level: Federal)

# Title: Improving Buprenorphine Retention with Transcutaneous Auricular Neurostimulation for Patients with Co-occuring Posttraumatic Stress Disorder and Opioid Use Disorder
Start: 2023-09-01 / End: 2024-08-31 Primary Investigators: Sprunger, Joel PhD Investigators: Welge, Jeffrey PhD; Winhusen, T PhD Grant Sponsor: National Institute on Drug Abuse 0.00 (level: Federal)

#U01DA050330 Title: IND-Enabling Pre-Clinical Studies to Accelerate the Clinical Development of a Humanized Anti-Cocaine Monoclonal Antibody
Start: 2019-09-15 / End: 2024-07-31 Primary Investigators: Norman, Andrew PhD Investigators: Amlal, Hassane PhD; Kirley, Terence PhD; Rubinstein, Jack MD; Webster, Rose Grant Sponsor: National Institute on Drug Abuse 4056896.00 (level: Federal)

#U01DA050330 Title: IND-Enabling Pre-Clinical Studies to Accelerate the Clinical Development of a Humanized Anti-Cocaine Monoclonal Antibody
Start: 2019-09-15 / End: 2024-07-31 Primary Investigators: Norman, Andrew PhD Investigators: Amlal, Hassane PhD; Kirley, Terence PhD; Rubinstein, Jack MD; Webster, Rose Grant Sponsor: National Institute on Drug Abuse 0.00 (level: Federal)

#R21AI165171 Title: Biomarkers of Replication and Injury in HBV/HIV Coinfection
Start: 2021-07-12 / End: 2024-06-30 Primary Investigators: Sherman, Kenneth MD,PhD Investigators: Blackard, Jason PhD Grant Sponsor: National Institute of Allergy and Infectious Diseases 443976.00 (level: Federal)

#60071380 OSU (UM1DA049417 NIH NIDA) Title: Optimizing HEALing in Ohio Communities (OHIO)
Start: 2019-04-17 / End: 2024-03-31 Primary Investigators: Winhusen, T PhD Investigators: Brown, Jennifer PhD; Lyons, Michael MD; McMullan, Jason MD Grant Sponsor: National Institute on Drug Abuse 15781558.00 (level: Federal)

#R13AI071925 Title: HIV and Liver Disease Conference
Start: 2021-04-12 / End: 2024-03-31 Primary Investigators: Sherman, Kenneth MD,PhD Grant Sponsor: National Institute of Allergy and Infectious Diseases 65001.00 (level: Federal)

#R33DA048439 Title: PHASE II-Omics analysis of HIV during synthetic opioid exposure
Start: 2022-01-01 / End: 2024-01-31 Primary Investigators: Blackard, Jason PhD Investigators: Brown, Jennifer PhD; Lyons, Michael MD; Medvedovic, Mario PHD; Sherman, Kenneth MD,PhD Grant Sponsor: National Institute on Drug Abuse 1220730.00 (level: Federal)

#T98HP33422 Title: SAFE T 2019 - Opioid Workforce Expansion Program (OWEP)
Start: 2019-09-01 / End: 2023-12-31 Primary Investigators: Brubaker, Michael Investigators: Acquavita, Shauna Grant Sponsor: Health Resources and Services Administration 1349807.00 (level: Federal)

#ODMHA 2300761 (SAMHSA H79TI085753) Title: State Opioid and Stimulant Response (SOS) 3.0
Start: 2022-09-30 / End: 2023-09-29 Primary Investigators: Ryan, Richard MD Investigators: Freiermuth, Caroline MD Grant Sponsor: Substance Abuse & Mental Health Services Administration 150000.00 (level: Federal)

#5K23DA042130-01A1 Title: Twitter-Based Intervention for Young Adult African American Blunt Smokers
Start: 2017-08-15 / End: 2023-07-31 Primary Investigators: Montgomery, La'trice PhD Grant Sponsor: National Institute on Drug Abuse 726280.00 (level: Federal)

#R01DA044248 Title: EMPOWER: Evaluating the ability to reduce Morphine equivalent dose for chronic Pain patients receiving Opioid-therapy through a Web-based E-Health self-management program: a Randomized multi-site Clin
Start: 2017-09-01 / End: 2023-06-30 Primary Investigators: Winhusen, T PhD Investigators: Elder, Nancy MD; Regan, Saundra PhD; Welge, Jeffrey PhD Grant Sponsor: National Institute on Drug Abuse 2550410.50 (level: Federal)

#U01DA048525 Title: First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody
Start: 2019-07-01 / End: 2023-04-30 Primary Investigators: Norman, Andrew PhD Investigators: Geracioti, Thomas MD; Kirley, Terence PhD; Nelson, Erik MD; Ridgway, William MD; Webster, Rose ; Welge, Jeffrey PhD Grant Sponsor: National Institute on Drug Abuse 8474481.00 (level: Federal)

#03140014IN0223 Title: UC Early Intervention Program - Integrated Naloxone Access and Infrastructure (IN23)
Start: 2021-09-30 / End: 2023-03-31 Primary Investigators: Freiermuth, Caroline MD; Lyons, Michael MD Investigators: Jarrell, Kelli MD Grant Sponsor: Substance Abuse & Mental Health Services Administration 93250.00 (level: Federal)

#Services Agreement / ISR 117-10246 Title: An evaluation of vertical transmission of hepatitis C virus (HCV) and natural history of chronic HCV in pregnant women with subsequent treatment post-partum
Start: 2019-08-01 / End: 2023-01-01 Primary Investigators: Blackard, Jason PhD Grant Sponsor: Gilead Sciences, Inc. 75855.00 (level: Industry)


Recently Completed Projects

#AGO Contract #12545 Title: Identifying genetic markers associated with opioid use disorder
Start: 2020-03-01 / End: 2022-12-31 Primary Investigators: Freiermuth, Caroline MD Investigators: Brown, Jennifer PhD; Lyons, Michael MD Grant Sponsor: Ohio Attorney General 2787805.00 (level: Ohio, State of)

#R21DA049253 Title: DAT18-09 Maternal opioid exposure and executive function evaluation in the mouse
Start: 2019-09-01 / End: 2022-08-31 Primary Investigators: Reyes, Teresa PhD Investigators: Wohleb, Eric PhD Grant Sponsor: National Institute on Drug Abuse 441375.00 (level: Federal)

#NY UM1DA049417 Title: NIDA CTN-0112: Optimal Policies to Improve Methadone Maintenance Adherence Long term (OPTIMMAL Study)
Start: 2021-08-01 / End: 2022-07-31 Primary Investigators: Winhusen, T PhD Investigators: Wilder, Christine MD,MHES Grant Sponsor: National Institute on Drug Abuse 134468.00 (level: Federal)

#800005519-01UG/U01DA040381 Title: Cohort Studies of HIV/AIDS and Substance Abuse in Miami
Start: 2015-09-15 / End: 2022-05-31 Primary Investigators: Sherman, Kenneth MD,PhD Grant Sponsor: National Institute on Drug Abuse 805035.00 (level: Federal)

#1802163 / DA143396 Title: Immune correlates of long-term success with DAA therapy in HCV/HIV infected people who inject drugs
Start: 2018-02-01 / End: 2022-05-31 Primary Investigators: Sherman, Kenneth MD,PhD Grant Sponsor: National Institute on Drug Abuse 58535.00 (level: Federal)

#K01DA045295 Title: Recruitment of endocannabinoid signaling in the ventral tegmental area and stressinduced escalation of cocaine intake
Start: 2020-05-01 / End: 2022-04-30 Primary Investigators: McReynolds, Jayme Grant Sponsor: National Institute on Drug Abuse 228716.49 (level: Federal)

#R61DA048439 Title: Omics analysis of HIV during synthetic opioid exposure
Start: 2019-03-01 / End: 2021-12-31 Primary Investigators: Blackard, Jason PhD Investigators: Brown, Jennifer PhD; Lyons, Michael MD; Medvedovic, Mario PHD; Sherman, Kenneth MD,PhD Grant Sponsor: National Institute on Drug Abuse 2073107.00 (level: Federal)

#EMF Research Grant Title: Better Prescribing Better Treatment Program: Innovations to Improve Opioid Prescribing for Acute Pain
Start: 2020-12-15 / End: 2021-12-14 Primary Investigators: Freiermuth, Caroline MD Grant Sponsor: Emergency Medicine Foundation 15000.00 (level: Non Profit)

#R01DK108362 Title: Hepatitis E in HIV-Infected Patients
Start: 2015-09-23 / End: 2021-08-31 Primary Investigators: Sherman, Kenneth MD,PhD Investigators: Blackard, Jason PhD; Shata, Mohamed Tarek MD, PhD Grant Sponsor: National Inst of Diabetes and Digestive and Kidney Disease 1374995.00 (level: Federal)

#UFDSP00011086 / PCORI HPC-1503-27891 Title: THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders
Start: 2016-03-01 / End: 2021-02-28 Primary Investigators: Sherman, Kenneth MD,PhD Grant Sponsor: Patient Centered Outcomes Research Institute 227185.00 (level: Non Profit)

#R01 AI065256 Title: HIV Antiretroviral Therapy and Hepatic Injury
Start: 2016-02-15 / End: 2021-01-31 Primary Investigators: Sherman, Kenneth MD,PhD Investigators: Blackard, Jason PhD; Shata, Mohamed Tarek MD, PhD Grant Sponsor: National Institute of Allergy and Infectious Diseases 2112277.00 (level: Federal)